Replies to post #117625 on Biotech Values

[DewDiligence]

Re: Xarelto vs Lovenox in immobilized patients (MAGELLAN study)

From the article you posted:

Johnson & Johnson is trying to identify patients who may be at higher risk for bleeding to help control the unwanted effects, DiBattiste said in an interview. “We have demonstrated efficacy and we want to understand better how the risks and benefits play out,” he said. “We need to do a deeper dive.”

The bold-faced text is corporate-speak for saying that Xarelto is probably dead in this indication. Notably absent in the newswire reports is any statement from JNJ or Bayer that the companies still intend to submit Xarelto for approval in this indication.